Table 1 Course of the trial.
IFN gamma | Placebo | |
|---|---|---|
Randomized patients | 18 | 14 |
Treatment interruptions | 2 (11.1%) | 4 (28.6%) |
Voluntary abandoners | 2 (11.1%) | 2 (14.3%) |
Deaths | 0 | 2 (14.3%) |
Completed 6 months of treatment | 16 (88.9%) | 10 (71.4%) |
Follow-up withdrawals | 3 (16.7%) | 2 (14.3%) |
Voluntary abandoners | 1 (5.5%) | 0 |
Deaths | 2 (11.1%) | 2 (14.3%) |
Completed 12 months of follow-up | 13 (72.2%) | 8 (57.1%) |
Total deaths | 2 (11.1%) | 5* (35.7%) |